News

Nivolumab Plus Low-Dose Ipilimumab Generates Long-term Benefit in Metastatic Colorectal Cancer

08/11/2022

According to 4-year follow-up results from a phase 2 trial, nivolumab plus low-dose ipilimumab demonstrates durable benefit for previously treated patients with MSI-high/MMR-deficient metastatic colorectal cancer.

According to 4-year follow-up...

08/11/2022

Oncology

Erika Martinelli, MD, PhD, University of Campania “Luigi Vanvitelli”

Videos

Third-Line Cetuximab Rechallenge Demonstrates Therapeutic Effectiveness in Metastatic Colorectal Cancer

07/03/2022

Erika Martinelli, MD, PhD, discusses findings from a follow-up analysis of the CRICKET and CAVE trials evaluating third-line cetuximab rechallenge combined with irinotecan or avelumab for patients with RAS wild-type metastatic colorectal...

Erika Martinelli, MD, PhD,...

07/03/2022

Oncology

Videos

Tucatinib Plus Trastuzumab Yields Clinically Meaningful Antitumor Activity in HER2-Positive Metastatic Colorectal Cancer

07/02/2022

John Strickler, MD, discusses results from the primary analysis of the phase 2 MOUNTAINEER trial, which demonstrated clinically meaningful antitumor activity with tucatinib plus trastuzumab for patients with HER2-positive metastatic...

John Strickler, MD, discusses...

07/02/2022

Oncology

Videos

Optimal Maintenance Strategy After Anti-EGFR-Based Induction Therapy in Metastatic Colorectal Cancer

07/02/2022

Alessandra Raimondi, MD, discusses results from an individual patient data pooled analysis of the Valentino and Panama clinical trials exploring the optimal maintenance treatment strategy following anti-EGFR-based induction therapy for...

Alessandra Raimondi, MD,...

07/02/2022

Oncology

Videos

Impact of Coexisting BRAF V600E Mutations on the Tumor Microenvironment in MSI-High or MMR-Deficient Colorectal Cancer

07/02/2022

Mohamed Salem, MD, discusses findings from a study exploring the impact of a BRAF V600E mutation on immunologic characteristics of the tumor microenvironment and associated genomic alterations in microsatellite instability (MSI)-high or...

Mohamed Salem, MD, discusses...

07/02/2022

Oncology

Videos

Botensilimab Plus Balstilimab Shows Promising Activity in Heavily Pretreated Metastatic Colorectal Cancer

07/02/2022

Anthony El-Khoueiry, MD, discusses results from an analysis of patients with microsatellite stable colorectal cancer treated with botensilimab plus balstilimab in an expanded phase 1a/b study.

Anthony El-Khoueiry, MD,...

07/02/2022

Oncology

Conference Coverage

Panitumumab Plus mFOLFOX6 Significantly Improves OS in Metastatic Colorectal Cancer

06/29/2022

Janelle Bradley ;

Findings from the phase 3 PARADIGM trial reveal panitumumab combined with mFOLFOX6 significantly improved OS vs bevacizumab plus mFOLFOX6 among patients with RAS wild-type and left-sided metastatic colorectal cancer.

Findings from the phase 3...

06/29/2022

Oncology

Conference Coverage

Botensilimab Plus Balstilimab Shows Promise For Microsatellite Stable Metastatic Colorectal Cancer

06/29/2022

Allison Casey ;

Novel immunotherapy combination botensilimab plus balstilimab demonstrated promising activity in heavily pretreated patients with microsatellite stable metastatic colorectal cancer, according to an analysis of an ongoing phase 1a/b trial.

Novel immunotherapy combination...

06/29/2022

Oncology

News

Sequential vs Combination Treatment With Fluoropyrimidines Plus Bevacizumab and Oxaliplatin for Metastatic Colorectal Cancer

06/14/2022

Allison Casey ;

Sequential treatment with fluoropyrimidines plus bevacizumab and oxaliplatin demonstrates superiority to combination treatment with this regimen for patients with metastatic colorectal cancer, according to findings from the phase 3 C-cubed...

Sequential treatment with...

06/14/2022

Oncology

News

Treatment Intensification With Modified FOLFOXIRI Plus Panitumumab Provides No Added Benefit in Colorectal Cancer

06/14/2022

Allison Casey ;

Intensification of upfront chemotherapy with modified FOLFOXIRI plus panitumumab as initial treatment for patients with metastatic colorectal cancer demonstrates no added benefit, according to the phase 3 TRIPLETE study.

Intensification of upfront...

06/14/2022

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology